RSS-Feed abonnieren
DOI: 10.1055/s-0030-1271066
© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG
DHEA-Substitution: Ist 7-Keto-DHEA die bessere Substanz?
Ein ÜberblickPublikationsverlauf
Publikationsdatum:
27. Juni 2011 (online)
Zusammenfassung
Das sog. DHEA-Mangelsyndrom geht nicht selten mit einem beschleunigten Alterungsprozess einher. Patienten mit konstant verminderten DHEA-Werten haben möglicherweise ein erhöhtes Risiko für kardiovaskuläre Krankheiten, Immundefizit, Infektionen, Autoimmunkrankheiten und evtl. auch für bestimmte maligne Krankheiten. Eine hochdosierte DHEA-Gabe kann zu einer Erhöhung der Sexualhormone führen, was ggf. mit einem höheren Prostata- bzw. Brustkrebsrisiko einhergehen kann. 7-Keto-(3-Acetyl-7-Oxo-)DHEA wird nicht in potenziell problematische Sexualhormone metabolisiert. Eine individuelle laborkontrollierte Low-dose 7-Keto-DHEA-Gabe kann daher bei den richtigen Indikationen sehr effektiv sein.
Schlüsselwörter
DHEA - 7-Keto-(3-Acetyl-7-Oxo-)DHEA - DHEA Deficiency Syndrome (DDS)
Literatur
- 1 Alhaj et al. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology. 2006; 188 541-551
- 2 Arnlöv J, Pencina M J, Amin S et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006; 145 176-184
- 3 Barrett-Connor E, Khaw K T, Yen S S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986; 315 1519-1524
- 4 Boggs W. DHEA restores oxidative balance in type II diabetes. Medscape; 2007
- 5 Bulbrook R D, Hayward J L, Spicer C C. Abnormal excretion of urinary steroids by women with early breast cancer. Lancet. 1962; 2 1238-1240
- 6 Bulbrook R D, Hayward J L, Spicer C C. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971; 2 395-398
- 7 Chen T T et al. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids. 1977; 12 409-413
- 8 Cleary M P, Fisk J F. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes. 1986; 10 193-204
- 9 Coleman D L, Leiter E H, Applezweig N. Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/KsJ-db/db). Endocrinology. 1984; 115 239-243
- 10 Coleman D L, Leiter E H, Schweizer R W. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes. 1982; 31 830-833
- 11 Coleman D L, Schweizer R W, Leiter E H. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes. 1984; 33 26-32
- 12 Davidson M. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med. 2000; 23 300-310
- 13 De Peretti E, Forest M G. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endocrinol Metab. 1978; 47 572-577
- 14 Fukui M, Kitagawa Y, Nakamura N et al. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis. 2005; 181 339-344
- 15 Henderson E, Yang J Y, Schwartz A. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses. 1992; 8 625-631
- 16 Henwood S M, Weeks C E, Lardy H. An escalating dose oral gavage study of 3beta-acetoxyandrost-5-ene-7,17-dione (7-oxo-DHEA-acetate) in rhesus monkeys. Biochem Biophys Res Commun. 1999; 254 124-126
- 17 Kahn C. Beyond the double helix: DNA and the quest for longevity. A thorough and highly readable “inside” account of DHEA research. New York: Times Books; 1985: 143
- 18 Kawano H, Yasue H, Kitagawa A et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003; 88 3190-3195
- 19 Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94 606-616
- 20 Kleine-Gunk B. Anti-Aging-Medizin – Hoffnung oder Humbug?. Deutsches Ärzteblatt. 2007; 104 http://www.aerzteblatt.de/V4/archiv/lit.asp?id=56301%2522%2520%255Cl%2520%2522nr28 28, http://www.aerzteblatt.de/V4/archiv/lit.asp?id=56301%22%20%5Cl%20%22nr29 29
- 21 Lardy H, Kneer N, Wei Y et al. Ergosteroids. II: biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids. 1998; 63 158-165
- 22 Löffler G, Petrides W et al. Physiologische Chemie. 8. Aufl. Berlin: Springer; 2007
- 23 Loria M, Regelson W, Padgett D A. Immune Response Facilitation and Resistance to Virus and bacterial Infections with Dehydroepiandrosterone (DHEA). In: Kalimi M, Regelson W, eds. The biologic Role of Dehydroepiandrosterone (DHEA). New York: Walter de Gruyter; 1990: 107-130
- 24 Loria R M. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids. 2002; 67 953-966
- 25 Loria R M, Padgett D A. Androstenediol regulates systemic resistance against lethal infections in mice. Ann NY Acad Sci. 1993; 3-95
- 26 Martina V, Benso A, Gigliardi V R et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf ). 2006; 64 260-264
- 27 Nair K S, Rizza R A, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006; 355 1647-1659
- 28 Nyce J W, Magee P N, Hard G C, Schwartz A G. Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. Carcinogenesis. 1984; 5 57-62
- 29 Orentreich N, Brind J L, Rizer R L, Vogelman J H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984; 59 551-555
- 30 Pashko L L, Schwartz A G. Effect of food restriction, dehydroepiandrosterone, or obesity on the binding of 3H-7,12-dimethylbenz(alpha)anthracene to mouse skin DNA. J Gerontology. 1983; 38 8-12
- 31 Anonym. DHEA: the last elixir. Prescrire International. 2002; 11 118-123
- 32 Schmidt P J, Daly R C, Bloch M et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005; 62 154-162
- 33 Schulz S, Klann R C, Schönfeld S, Nayce J W. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res. 1992; 52 1372-1376
- 34 Schulte-Uebbing C. DHEA Substitution. In: Umweltbedingte Frauenkrankheiten. Lehrbuch [Environmentally-induced Gynaecological Illnesses], textbook for gynaecologists, naturopaths and environmental physicians. Stuttgart: Sonntag; 1994
- 35 Schulte-Uebbing C, Schlett S. Vitamin D in der gynäkologischen Praxis, Ergebnisse einer Anwendungsbeobachtung. CO MED. 2010; 3 3-10
- 36 Schulte-Uebbing C. Ursachen von Endometriose: Schlussfolgerungen aus Praxiserfahrung und Nachuntersuchung. ZKM. 2010; 2 18-21
- 37 Schulte-Uebbing C, Schlett S. Kolpitis und Co. – vaginale Vitamin-D-Applikation hilft. Gyn Geb. 2010; 3 2-3
- 38 Schulte-Uebbing C. Mammovision – ein komplementäres Mamma-Diagnostik-Verfahren. ZÄN (zaenmagazin). 2010; 2 13-19
- 39 Schulte-Uebbing C. Infrarot-Thermographie, endokrinologische Einflussfaktoren. EHK. 2010; 59 226-232
- 40 Schulte-Uebbing C. Toxikologische, infektiologische und immunologische Aspekte des Mammakarzinoms. Klinikum Rechts der Isar der Technischen Universität München; 2009: 4-9
- 41 Schulte-Uebbing C. 9. Konferenz der GSAAM. München; 2009: 4-9
-
42 Schulte-Uebbing C. Applied anti aging medicine. 8th International Congress Plastic Surgery, Bukarest, 5/2008. Schulte-Uebbing C. Anti aging and preventive medicine aspects. Int. Health Academy, Meran, 5/2008
- 43 Schulte-Uebbing C. Umweltmedizinische Aspekte des Anti-Aging. Umweltmedizinische Aspekte des Anti-Aging, Vorträge und Workshops, Internationale Ärztekongresse „Anti-Aging“. Universität Heidelberg, Berlin, Wien 2001–2003
- 44 Zahn V, Schulte-Uebbing C. Lehrbuch der Umweltmedizin. (Erstes deutschsprachiges Lehrbuch für Umweltmediziner, 560 Seiten.) München: Umgewe; 1990
- 45 Schulte-Uebbing C. Steroids as inhibitors of human placental Glutathione-S-Transferase by steroids. Aachen; Vortrag “Placenta-Kongreß” 1986
- 46 Schulte-Uebbing C. Inhibition of human placental glutathione-S transferase by steroids. Placenta. 1987; 1
- 47 Schulte-Uebbing C, Dibbelt L, Kuss E. Human placental glutathione-S transferase: interactions with steroids. Biol Chem Hoppe-Seyler. 1988; 369 23-28
- 48 Schwartz A G. Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res. 1979; 39 1129-1132
- 49 Schwartz A G, Hard G C, Pashko L L et al. Dehydroepiandrosterone: an antiobesity and anti-carcinogenic agent. Nutr Cancer. 1981; 3 46-53
- 50 Schwartz A G, Nyce J W, Tannen R H. Inhibition of tumorigenesis and autoimmune development in mice by dehydroepiandrosterone. Mod Aging Res. 1984; 6 177-184
- 51 Schwartz A G, Fairman D K, Pashko L L. The biological Significance of Dehydroepiandrosterone. In: Kalimi M, Regelson W, eds. The biologic Role of Dehydroepiandrosterone (DHEA). New York: Walter de Gruyter; 1990
- 52 Tworoger S S, Missmer S A, Eliassen A H et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15 967-971
- 53 Wallace M B, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs. androstenedione supplementation in men. Med Sci Sports Exerc. 1999; 31 1788-1792
- 54 Wolkowitz O M, Kramer J H, Reus V I et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003; 60 1071-1076
- 55 Wolkowitz O M, Reus V I, Keebler A et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psych. 1999; 156 646-649
- 56 Yen T T, Allan J A, Pearson D V, Acton J M, Greenberg M M. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids. 1977; 12 409-413
- 57 Yang N C, Jeng K C, Ho W M, Hu M. ATP depletion is an important factor in DHEA-induced growth inhibition and apoptosis in BV-2 cells. Life Sci. 2002; 70 1979-1988
- 58 Young E A, Haskett R F, Grunhaus L et al. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry. 1994; 51 701-707
- 59 Enomoto M, Adachi H, Fukami A et al. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru Study). J Am Geriatr Soc. 2008; 56 994-998
- 60 Hayashi T, Esaki T, Muto E et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen, the possible role of nitric oxide. Arterioscler Thromb Vasc Biol. 2000; 20 782
- 61 Loria R M, Padgett D A, Huynh P N. Regulation of the immune response by dehydroepiandrosterone and its metabolite. J Endocrinol. 1996; 150 S209-S220
- 62 Merril C R, Harrington M G. Plasma dehydroepiandrosterone levels in HIV infection (letter). JAMA. 1989; 261 1149
- 63 Mulder J W, Frissen P H, Krijnen P et al. Serum dehydroepiandrosterone (DHEA) levels in asymptomatic HIV-1 infected subjects. J Infect Dis. 1992; 165 413-418
- 64 Panjari M, Davis S R. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update May 1,. 2007; 13 239-248
- 65 Piketty C, Jayle D et al. DHEA might lower “good cholesterol”. Proc Natl Acad Sci USA. 2001; 98 8145-8150
- 66 Rosack J et al. Disappointing data confound claims for DHEA effectiveness. Psychiatric News. 2003; 38 38
- 67 Yen S S C, Morales A J, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Am J Med Sci. 1996; 311 205-210
Prof. Dr. med. Claus Schulte-Uebbing
Weinstraße 7 A
80333 München
eMail: dr-schulte-uebbing@t-online.de
Prof. Dr. med. Claus Schulte-Uebbing ist Frauenarzt mit den Spezialisierungen Onkologie, Immunologie, Endokrinologie, Umweltmedizin und leitet das Umweltmedizinische Therapiezentrum am Dom in München. Zudem arbeitet er als umweltmedizinischer Gutachter und ist Autor zahlreicher medizinischer Fach- und Lehrbücher.